Catalyst Biosciences Inc. (CBIO): What Technical Indicators Show


Catalyst Biosciences Inc. (NASDAQ:CBIO) saw an upside of 2.73% to $0.31 after adding $0.01 on Wednesday. The 5-day average trading volume is 1,123,153 shares of the company’s common stock. It has gained $0.3200 in the past week and touched a new high 5 times within the past 5 days. An average of 2,007,878 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 949,355.

CBIO’s 1-month performance is -4.05% or -$0.1944 on its low of $0.1950 reached on 01/13/23. The company’s shares have touched a 52-week low of $0.06 and high of $0.40, with the stock’s rally to the 52-week high happening on 01/09/23. YTD, CBIO has lost -9.05% or -$0.2189 and has reached a new high 4 times. However, the current price is down -24.18% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

CBIO stock has a beta of 0.93. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.27 while the price-to-book (PB) in the most recent quarter is 0.32.

Catalyst Biosciences Inc.’s quick ratio for the period ended June 29 was 18.40, with the current ratio over the same period at 18.40. In terms of profitability, the gross margin trailing 12 months is -0.60%. The firm’s gross profit as reported stood at $42000.0 against revenue of $7.34 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income shrunk -308.4% to -$4.88 million, while revenue of $51.63 million was 1157.99% off the previous quarter. Analysts expected CBIO to announce -$0.24 per share in earnings in its latest quarter, but it posted $1.64, representing a 783.30% surprise. EBITDA for the quarter stood at more than -$5.13 million. CBIO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.64 million, with total debt at $1.42 million. Shareholders hold equity totaling $31.49 million.

Let’s look briefly at Catalyst Biosciences Inc. (CBIO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 32.67% to suggest the stock is trending Neutral, with historical volatility in this time period at 447.50%.

The stock’s 5-day moving average is $0.2784, reflecting a +23.39% or $0.0585 change from its current price. CBIO is currently trading -38.65% above its 20-day SMA, -84.34% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -43.89% and SMA200 by-53.24%.

Stochastic %K and %D was 21.29% and 18.09% and the average true range (ATR) pointed at 0.0511. The RSI (14) points at 32.52%, while the 14-day stochastic is at 24.97% with the period’s ATR at 0.0494. The stock’s 9-day MACD Oscillator is pointing at -0.0181 and -0.1284 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for CBIO stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate CBIO as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is CBIO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $3.00 and a high of $3.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Catalyst Biosciences Inc. (CBIO) stock is $3.00.


Please enter your comment!
Please enter your name here